Physicians' Academy for Cardiovascular Education

Blood Pressure 2017: Translating latest insights to clinical practice- key lessons from SPRINT/HOPE-3

Lecture - May 6, 2017 - Beijing, China - Prof. Richard Hobbs,MD Oxford, United Kingdom

This lecture was part of a Cardio Diabetes Master Class 'CVM Summit 2017, held on May 5, 2017 in Beijing, China

Educational information

The educational objectives of the program were:

◾To explore mechanisms and common pathways underlying the development of cardiovascular disease and diabetes

◾To review and discuss the importance of glucose management and the rationale for early intervention strategies in patients with diabetes

◾To discuss the role of anti-diabetic therapy, in particular the use of DPP4 inhibitors and TZD’s, in a risk based intervention strategy that targets glucose control and cardiovascular risk factors

◾To discuss therapies that work through other insulin-related mechanisms, including insulin resistance in order to reduce the incidence of cardiovascular events; especially in high-risk patient populations with a history of an ACS event and multiple risk factors

◾To evaluate the current guidelines for the management of patients with diabetes and high CV risk, and identify potential novel targets for therapy in this high-risk patient group

◾To discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multirisk patients


Prof Richard Hobbs is currently Professor and Head of the Department of Primary Health Care. He is the Director of the NIHR National School for Primary Care Research (2009-) and was co-Director of the Quality and Outcomes (QOF) Review Panel from 2005-09. He sits on several national and international scientific and research funding boards, including the Council of the British Heart Foundation and the Board of the British Primary Care Cardiovascular Society. He currently chairs the Council for Cardiovascular Primary Care, European Society of Cardiology (ESC); the Prevention and Care Board, British Heart Foundation; and the European Primary Care Cardiovascular Society (EPCCS).


The master class is supported by an unrestricted educational grant provided by Takeda Pharmaceuticals Inc

Download slides as PDF

View slides

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: